Deborah Dunsire is a seasoned executive with extensive experience in the pharmaceutical and biotech industries. Currently serving as a Board Member for McKesson, Syros Pharmaceuticals, and Ultragenyx since 2024, 2021, and 2014 respectively, Dunsire has also held significant leadership positions including CEO of Lundbeck from 2018 to 2023, where the focus was on improving outcomes for individuals with mental health issues. Previous roles include Board Member at Alexion Pharmaceuticals and Allergan, and CEO of XTuit Pharmaceuticals and FORUM Pharmaceuticals, where innovative strategies targeted serious health conditions. Dunsire's leadership at Takeda and Millennium: The Takeda Oncology Company marked a transformative era for the organizations, emphasizing integrated approaches in oncology and immunology. Dunsire obtained a degree in General Medicine from the University of the Witwatersrand from 1980 to 1985 after graduating from Westville Girls High School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Ultragenyx Pharmaceutical
10 followers
Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.